ELYM Stock Overview
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Eliem Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.76 |
52 Week High | US$3.72 |
52 Week Low | US$2.34 |
Beta | 0.50 |
1 Month Change | 4.55% |
3 Month Change | 1.10% |
1 Year Change | -10.10% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -82.64% |
Recent News & Updates
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08Recent updates
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Shareholder Returns
ELYM | US Biotechs | US Market | |
---|---|---|---|
7D | -1.1% | 0.9% | 0.4% |
1Y | -10.1% | 10.3% | 28.8% |
Return vs Industry: ELYM underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ELYM underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ELYM volatility | |
---|---|
ELYM Average Weekly Movement | 7.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELYM has not had significant price volatility in the past 3 months.
Volatility Over Time: ELYM's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 37 | n/a | https://eliemtx.com |
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Eliem Therapeutics, Inc. Fundamentals Summary
ELYM fundamental statistics | |
---|---|
Market cap | US$76.49m |
Earnings (TTM) | -US$39.24m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs ELYM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ELYM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$39.24m |
Earnings | -US$39.24m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ELYM perform over the long term?
See historical performance and comparison